Skip to main content
OpenTrials
Completed

NCT Number: NCT01677338

Phase 2 Study to Evaluate the Preliminary Performance of the C13-URA Breath Test Kit in Dyspeptic Subjects

This study is a multi-center, open-label comparison study and aimed to evaluate the preliminary performance of this 13C-uracil GEBT to examine its abilities of identifying abnormal (delayed) gastric emptying rates in subjects.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

21 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Compass Research, Orlando, Florida, United States

Loading trial locations.

About this study

Approximately equal numbers of subjects will be enrolled in each of the 2 groups (with normal gastric emptying, and with delayed gastric emptying (gastroparesis)) to complete at least 10 subjects per group.

The subjects will first have their gastric emptying rates investigated by scintigraphy using the Solid Test Meal containing 500 uCi 99mTc sulfur colloid at Visit 1. Second, the subjects will have their gastric emptying rates investigated by scintigraphy and 13C-uracil GEBT simultaneously using the Semi solid Test Meal containing 500 uCi 99mTc sulfur colloid and 100 mg of 13C-uracil, respectively, at Visit 2. A comparison will be made between the results obtained at Visits 1 and 2 along with a comparison of the data obtained during Visit 2 for evaluation of the 13C-uracil GEBT.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Body mass index [range is 18.0 to 33.0 kg/m2
  • Subjects with any upper GI symptoms
  • Stable creatinine

Exclusion criteria

  • History of known peptic ulcers or stomach cancer.
  • History of stomach surgery or resection
  • History of significant hypersensitivity, intolerance, or allergy to any drug compound, food or other substance, unless approved by the investigator
  • History of alcoholism or drug abuse
  • History or presence of clinically significant GI, cardiovascular, central nervous system, hepatic, or renal disease; or other conditions
  • History of eating disorders
  • History or presence of an abnormal ECG, which, in the opinion of the investigator, is clinically significant

Treatment and study plan

13C-uracil

Drug

PO, the Semi-solid Test Meal containing 100 mg of 13C-uracil . Perform the Breath Test.

Other names: C13-URA

99mTc sulfur colloid

Drug

PO, the Solid Test Meal containing 500 uCi 99mTc sulfur colloid. Perform the Scintigraphy.

Other names: Technetium Tc 99m Sulfur Colloid Injection

Primary outcomes

  1. Expired 13CO2 concentrations

    Time frame: 6 hours

    Expired 13CO2 concentrations are obtained from breath test. The values will be calculated to Re(t)[B] semi-solid: remaining (%) of semi-solid test meal in stomach at t, t1/2[B] semi solid: half emptying time of semi-solid test meal , and tlag[B] semi-solid: lag time of semi-solid test meal.

Secondary outcomes

  1. Concentrations of 13C-uracil and its major metabolites in plasma and urine

    Time frame: 6 hours

    PK parameters of 13C-uracil and its major metabolites, DHU and UPA, including AUCt, AUC∞, Cmax, tmax, λz, and t1/2,z, will be calculated based on plasma and urine concentration for 13C-uracil and its metabolites, and expired 13CO2-excretion, which calculated based on expired 13CO2 concentrations

Sponsors and collaborators

Lead sponsor

Otsuka Pharmaceutical Co., Ltd.

Industry

Collaborators

  • Covance

Registry information

Official study title

A Multi-center, Open-label Comparison Study of a 13C-uracil Breath Test Versus 99mTechnetium Sulfur Colloid Gastric Emptying Scintigraphy to Evaluate Normal, and Delayed Gastric Emptying Time in Dyspeptic Subjects

Important dates

Study start
2013
Primary completion
2014
Study completion
2014
First posted
Sep 3, 2012
Registry last updated
Apr 8, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.